A phase III trial of how well pembrolizumab works in treating triple-negative breast cancer.

Skip to Content

Clinical Trial Details

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

A phase III trial of how well pembrolizumab works in treating triple-negative breast cancer.

Objective

Visit the National Cancer Institute's Web Site.

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

IRB Protocol Number
SWOG S1418 NCT#02954874

Clinical Trial Categories

  • Breast Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Concord Hospital
    250 Pleasant Street
    Concord, NH 03110
    Main: 603-225-2711
    Alternate: 800-327-0464